Metabolic Health Trajectories in Overweight Chinese Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study tracks adults aged 18–60 with overweight or obesity, with or without type 2 diabetes, to map five-year trajectories of metabolic phenotypes. Participants will use a digital health platform for data upload and receive lifestyle support, with comprehensive assessments at baseline, 2.5 years, and 5 years, plus annual brief follow-ups. The study compares metabolically healthy overweight/obesity, metabolically unhealthy overweight/obesity, and overweight/obesity with type 2 diabetes to understand changes in metabolic parameters, complication rates, and cardiovascular risk. The aim is to identify transition rates between phenotypes and the development of diabetic and cardiovascular events. The study is conducted at Zhujiang Hospital in Guangzhou, with eligibility focused on adults able to consent and using smartphone tools.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.
2. Age between 18 and 60 years (inclusive).
3. Meets at least one of the following overweight/obesity criteria: a) BMI ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.
4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.

Exclusion Criteria:

1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.
2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \< 0.1 mIU/L with FT4 \> upper normal limit; hypothyroidism: TSH \> 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.
3. Severe liver disease (Child-Pugh class B or C).
4. Renal insufficiency (estimated glomerular filtration rate \< 30 mL/min/1.73 m²).
5. Severe cardiac dysfunction (New York Heart Association class III or IV).
6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).
7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).
8. Active malignancy (diagnosed or treated within the last 3 years).
9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).
10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).
11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).
12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.
13. Pregnancy or planned pregnancy during the study period.
14. History of or planned organ transplantation.
15. Inability to operate the AI-based system or comply with follow-up procedures.
16. Concurrent participation in another interventional clinical trial that may influence the results of this study.
17. Unwilling or unable to provide informed consent.

Where it's running

• Zhujiang Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Hong Chen, Ph.D.
• Email: rubychfq@163.com
• Phone: +86 20 61643888

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood-count inflammation scores (SII and SIRI) to predict metabolic complications in adults with overweight or obesity

  This project will test whether two blood-count-based scores (SII and SIRI) can help predict metabolic complications and treatment response in adults with overweight or obesity.

  Recruiting University of Rijeka · Varaždin · NCT07431593

• Investigating insulin resistance using alpelisib in adults

  This study is testing if a drug called alpelisib can help us understand how insulin works in healthy adults compared to those at risk for type 2 diabetes.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06354088

• Eating window timing to improve blood sugar in adults with obesity and type 2 diabetes or at risk

  This study tests whether eating only during one of three nine-hour daily windows can improve blood sugar control in adults with obesity who have or are at risk for type 2 diabetes.

  Recruiting University of Toronto · Toronto, Ontario · NCT06118931

• Comparing two care strategies for preventing cardiovascular events in at-risk patients

  This study tests if a new care strategy based on a detailed look at coronary artery disease can better prevent heart problems in people at risk but without symptoms, compared to the usual approach.

  Recruiting at 122 sites Cleerly, Inc. · Chandler, Arizona and 124 other locations · NCT06112418

• App plus smart body fat scale program to help overweight people with schizophrenia or bipolar disorder lose weight

  See if using the Huawei Health app together with a smart body fat scale helps overweight people with schizophrenia or bipolar disorder lose weight and stay involved in their care.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT05866107

• Examining how fat tissue expands during overeating

  This study is testing how fat tissue in the body changes when people overeat for a short time to see how it affects their overall health, especially regarding obesity and metabolic issues.

  Recruiting Pennington Biomedical Research Center · Baton Rouge, Louisiana · NCT04583514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.